A "cure" for Parkinson's disease: Can neuroprotection be proven with current trial designs?

Movement Disorders

Volumn 19, Issue 5, 2004, Pages 491-498

  Clarke, Carl E ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Neuroprotection; Parkinson's disease; Randomised controlled trials

Indexed keywords

6 FLUORODOPA; 6 FLUORODOPAMINE; CARBON 11; CHOLINESTERASE INHIBITOR; DOPA; DOPAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; DOPAMINE TRANSPORTER; FLUORINE 18; IODINE 123; LEVODOPA; LIGAND; N SEC BUTYL 1 (2 CHLOROPHENYL) N METHYL 3 ISOQUINOLINECARBOXAMIDE; NEUROPROTECTIVE AGENT; OXIDOPAMINE; PLACEBO; PRAMIPEXOLE; RILUZOLE; ROPINIROLE; SELEGILINE; TRACER; TROPANE DERIVATIVE; UBIDECARENONE; ANTIPARKINSON AGENT;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC PROCEDURE; DISEASE CONTROL; DISEASE COURSE; DRUG MECHANISM; DRUG MONITORING; DRUG SAFETY; HEALTH ECONOMICS; HOSPITAL CARE; HUMAN; LONG TERM CARE; METHODOLOGY; MORTALITY; MOTOR DYSFUNCTION; NEUROIMAGING; NEUROPROTECTION; NEUROSURGERY; OUTCOMES RESEARCH; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; QUALITY OF LIFE; RATING SCALE; RELIABILITY; REVIEW; SAMPLE SIZE; SIDE EFFECT; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STATISTICAL ANALYSIS; SYMPTOMATOLOGY; TREATMENT OUTCOME; VALIDATION PROCESS; BRAIN; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; COST BENEFIT ANALYSIS; ECONOMICS; METABOLISM; RANDOMIZED CONTROLLED TRIAL; VASCULARIZATION;

ANTIPARKINSON AGENTS; BRAIN; COST-BENEFIT ANALYSIS; DOPAMINE AGONISTS; HUMANS; LEVODOPA; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS; SELEGILINE; TOMOGRAPHY, EMISSION-COMPUTED; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 3142547870     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/mds.20057     Document Type: Review

References (27)

1. The Parkinson Study Group. Mortality in DATATOP: a multicentre trial in early Parkinson's disease. Ann Neurol 1998;43:318-325.
2. Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole versus levodopa on Parkinson disease progression. JAMA 2002;287:1653-1661.
3. Whone A, Watts R, Stoessl A, et al. Slower progression of Parkinson's disease with ropinirole versus levodopa: the REAL-PET study. Ann Neurol 2003;54:93-101.
4. Clarke CE, Guttman M. Dopamine agonist monotherapy in Parkinson's disease. Lancet 2002;360:1767-1769.
5. Ravina BM, Fagan SC, Hart RG, et al. Neuroprotective agents for clinical trials in Parkinson's disease. Neurology 2003;60:1234-1240.
6. Schapira AHV. Parkinson's disease. BMJ 1999;318:311-314.
7. Holloway RG, Dick A. Clinical trial end points: on the road to nowhere? Neurology 2002;58:679-686.
8. Fahn S, Elton RL, Members of the UPDRS Development Committee. Unified Parkinson's disease rating scale. In: Fahn S, Marsden CD, Goldstein M, Calne DB, editors. Recent developments in Parkinson's disease. Vol. 2. New Jersey: Macmillan Healthcare Information; 1987. p 153-163.
9. 10 in early Parkinson disease: evidence of slowing of the functional decline. Arch Neurol 2002;59:1541-1550.
10. Olanow CW, Hauser RA, Gauger L, et al. The effect of deprenyl and levodopa on the progression of Parkinson's disease. Ann Neurol 1995;38:771-777.
11. The Parkinson Study Group. Effect of deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1989;321: 1364-1371.
12. Rakshi JS, Pavese N, Uema T, et al. A comparison of the progression of early Parkinson's disease in patients started on ropinirole or L-dopa: an 18F-dopa PET study. J Neural Transm 2002;109:1433-1443.
13. Clarke CE. Mortality from Parkinson's disease. J Neurol Neurosurg Psychiatry 2000;68:254-255.
14. Lees AJ, Parkinson's Disease Research Group of the United Kingdom. Comparison of the therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. BMJ 1995;311:1602-1607.
15. Ben-Shlomo Y, Churchyard A, Head J, et al. Investigation by Parkinson's Disease Research Group of United Kingdom into excess mortality seen with combined levodopa and selegiline treatment in patients with early, mild Parkinson's disease: further results of randomised trial and confidential inquiry. BMJ 1998; 316:1191-1196.
16. Parkinson Study Group. Does levodopa slow or hasten the rate of progression of Parkinson's disease? The results of the ELLDOPA trial. Neurology 2003;60(Suppl. 1):A80-A81.
17. The Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1993;328:176-183.
18. Clarke CE. Does levodopa therapy delay death in Parkinson's disease? A review of the evidence. Mov Disord 1995;10:250-256.
19. Miller R, Mitchell J, Lyon M, Moore D. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND) (Cochrane Review). The Cochrane Library. Oxford: Update Software, 2003.
20. Birks J, Melzer D, Beppu H. Donepezil for mild and moderate Alzheimer's disease (Cochrane Review). The Cochrane Library. Oxford: Update Software, 2003.
21. Wheatley K, Stowe R, Clarke C, Hills R, Williams A, Gray R. Evaluating drug treatments for Parkinson's disease: how good are the trials? BMJ 2002;324:1508-1511.
22. Marek K, Seibyl J, Parkinson Study Group. Beta-CIT scans without evidence of dopaminergic deficit (SWEDD) in the ELLDOPA-CIT and CALM-CIT studies: long-term imaging assessment. Neurology 2003;60(Suppl. 1):A293.
23. Parkinson Study Group, Holloway RG. Pramipexole versus levodopa as initial treatment for Parkinson's disease: a 4-year randomised controlled trial. Neurology 2002;58(Suppl. 3):A81-A82.
24. Morrish PK, Rakshi JS, Bailey DL, Sawle GV, Brooks DJ. Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with 18F-dopa PET. J Neurol Neurosurg Psychiatry 1998;64:314-319.
25. Guttman M, Stewart D, Hussey D, Wilson A, Houle S, Kish S. Influence of L-dopa and pramipexole on striatal dopamine transporter in early PD. Neurology 2001;56:1559-1564.
26. Cagnin A, Gerhard A, Banati R. In vivo imaging of neuroinflammation. Eur Neuropsychopharmacol 2002;12:581-586.
27. Bodick N, Forette F, Hadler D, et al. Protocols to demonstrate slowing of Alzheimer disease progression. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines. The Disease Progression Sub-Group. Alzheimer Dis Assoc Disord 1997;11(Suppl. 3):50-53.